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Background: Lysosomal storage disorders (LSD) are a rare cause of non immunological hydrops fetalis (NIHF) and
congenital ascites. The reported incidence is about 1%. The incidence of idiopathic NIHF is estimated to be about
18%.
Patients and methods: We report four cases with transient hydrops fetalis resulting from LSD and performed a
literature review on LSD with NIHF and congenital ascites in combination.
Results: At present, 12 different LSDs are described to be associated with NIHF or congenital ascites. Most patients
had a family history of NIHF, where the preceding sibling had not been examined. A diagnostic approach to the
fetus with NIHF due to suspected LSD either in utero or postnatal is suggested. Transient forms of NIHF and/or
ascites in association with MPS IVA, MPS VII and NPC are described for the first time in this publication.
Conclusions: LSD should be considered in transient hydrops. Enzymatic studies in chorionic villous sample or
amniotic cultured cells, once the most common conditions associated with fetal ascites or hydrops have been ruled
out, are important. This paper emphasizes the fact that LSD is significantly higher than the estimated 1% in
previous studies, which is important for genetic counseling as there is a high risk of recurrence and the availability
of enzyme replacement therapy for an increasing number of LSD.
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Clinical approachBackground
Hydrops fetalis is a serious fetal condition defined as an
abnormal accumulation of fluid in two or more fetal
compartments, including ascites, pleural and/or pericar-
dial effusion, and skin edema. In some patients, it may
also be associated with polyhydramnion and placental
edema. Isolated congenital ascites is usually considered
as part of the clinical picture of hydrops fetalis, in which
the severity of peripheral edema is of a mild degree and
ascites is the dominant clinical sign [1,2]. Hydrops fetalis* Correspondence: catharina.whybra@unimedizin-mainz.de
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reproduction in any medium, provided the orhas been a well-recognized fetal and neonatal condition
throughout history. Before routine immunization of Rh-
negative mothers in the 1970s, most cases of immuno-
logical hydrops were due to erythroblastosis from Rh
alloimmunization. More recent recognition of factors
other than isoimmune hemolytic disease that can cause
or be associated with hydrops fetalis led to the use of
the term non-immunological hydrops fetalis (NIHF).
Currently, NIHF (reported incidence of 1 in 2000–3000
pregnancies [3]) is more common, comprising 85-90% of
all described cases [4,5]. The precise incidence of
hydrops fetalis is difficult to elucidate, because many
cases are not detected prior to intrauterine fetal death
and some cases may resolve spontaneously in utero.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disproportionate share (3%) of overall mortality in the
perinatal period [6,7,8].
Inborn errors of metabolism (IEM) may cause hydrops
fetalis. Most of these are lysosomal storage diseases.
Today, around 14 different lysosomal storage diseases
(LSD) have been reported as being associated with NIHF
and congenital ascites [9,10,11]. The cause of the accu-
mulation of excessive fluid within the peritoneal cavity
in infants with LSD is a source of considerable contro-
versy in the literature [12]. The mechanism contributing
to the development of hydrops fetalis in storage diseases
may involve the obstruction of venous blood return
resulting from visceromegaly secondary to accumulation
of storage material [13]. Anemia may be a trigger, being
caused by either hypersplenism or the reduction of
erythropoietic stem cells caused by infiltrating storage
cells. Other conditions that may trigger ascites in LSD
are congestive heart failure, hypoproteinaemia and liver
dysfunction [12].
In this paper we present four cases with transient
NIHF and a literature review on the incidence of LSD in
NIHF. A diagnostic approach to the patient with NIHF
or ascites due to suspected LSD either in utero or post-
natally is established.
The purpose of this work is to report four cases, which
have in common a transient hydrops fetalis, normal ap-
pearance in the postnatal period and progressive deteri-
oration with time. All of them were diagnosised as LSD.
Until now transient hydrops fetalis in association with
LSD has been barely reported [14,15]. A mortality rate
of 100% of IEM in association with a NIHF is assumed
[16], however, transient NIHF with a good perinatal out-
come has hardly been described.
Case reports
Case I
In a term male neonate of non-consanguineous parents
with two healthy siblings (birth weight 3250 g, length
48 cm, head circumference 36 cm, Apgar Score 9/9/10,
umbilical artery pH 7,24), prenatal ultrasound revealed
hydrops fetalis with ascites at as early as 24 weeks of
gestation. Prenatal infection was ruled out in fetal blood
and any immunological causes were excluded. Amnio-
centesis showed a normal male karyotype. After birth he
was breathing spontaneously. He had a normal pheno-
typic appearance, bilateral inguinal hernia and a mild
hepatosplenomegaly, but no detectable ascites or pleural
effusion. Echocardiography and ophthalmological exam-
ination were normal. Neonatal cholestasis and icterus
praecox with elevated direct bilirubin was assessed.
Hepato-IDA-scintigraphy showed patent extrahepatic
biliary duct. Liver biopsy revealed foamy cells typically
seen in Niemann Pick disease. Enzymatic measurementsshowed normal values for sphingomyelinase, ß-glucosi-
dase, sialidase and acid lipase, excluding Niemann Pick
A disease (NPA), Gaucher disease and Wolman disease.
Variant Filipin staining led to the misdiagnosis of NPC.
Neonatal cholestasis was treated with ursodeoxycholic
acid, and then resolved spontaneously. Although the pa-
tient showed nearly normal neurological development
(slight language development retardation), mild joint
contractures and bilateral avascular necrosis of the fem-
oral head, NPC as the slowly progressive form was sus-
pected. Eight years later, the patient was presented in
our clinic for a trial of substrate reduction therapy of
NPC. The patient had no elevation of chitotriosidase
and no horizontal saccades typical for NPC. In contrast,
eye examination revealed corneal clouding. In addition,
hip dysplasia was seen. Detection of the deficiency of ß-
glucuronidase (0,0069 mU/ml) finally yielded the diag-
nosis of MPS VII.
Case II
The first child of non-consanguineous parents presented
with hydrops fetalis, in particular massive hydrothorax
(Figure 1a) at 22 weeks of gestation. A drainage of the
intra-thoracal fluid was established by ultrasound-guided
foeto-amniotic shunting at 24 weeks of gestation
(Figure 1b). Thereafter, the female fetus developed nor-
mally (Figure 1c) and was born by Caesarian section at
39 weeks of gestation (birth weight 3560 g, length 52 cm,
head circumference 35 cm, Apgar Score 9/10/10, umbil-
ical artery pH 7,34). 24 hours after birth the neonate of
normal phenotype was admitted to the neonatology ward
due to bradycardia and acrocyanosis. There was no evi-
dence of infection. Echocardiography and ECG were nor-
mal. Soon after, she was discharged home. At age three
years she showed toddling gait and weakness of musculus
quadriceps femoris, as well as beginning kyphoscoliosis.
N-acetyl-glucosamin-6-sulfat sulfatase deficiency with a
residual activity of 0,141 nmol/mg/17 h (normal 12-
26 nmol/mg/17 h) confirmed the diagnosis of MPS IVA.
Mutation Analysis revealed GALNS c.463 G→A in Exon
5 and Intron 13 (IVS13-1 G→A).
Case III
In this case, the parents were consanguineous. The
mother had had two previous pregnancies with spontan-
eous abortion. In the third pregnancy the fetus presented
with intrauterine hydrops fetalis. The male preterm was
born at 29 weeks of gestation by Caesarian sectio be-
cause of premature labour (birth weight 1550 g, length
41 cm, head circumference 27,5 cm, umbilical artery pH
7, 12). His neonatal period was uncomplicated. He could
walk at age 20 months and showed minor mental retard-
ation. At age one and a half years he developed a
kyphoscoliosis. The diagnosis of MPS IVA by detection
ab
c
Figure 1 a: 22 weeks of gestation and massive hydrothorax in
case II. b: 24 weeks of gestation, punction of hydrothorax and
insertion of a thoraco-amniotic shunt in case II. Correct placement of
the intrauterine shunt system. c: Regression of the hydrothorax at 31
weeks of gestation in case II.
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a residual activity of 0.234 nmol/mg/17 h ( normal 12–
26 nmol/mg/17 h) was only made four years later due to
continuing disproportionate growth retardation (length
far below 3rd percentile) and skeletal abnormalities
(thoracolumbar gibbus, ulnar deviation).
Case IV
The male fetus presented with intrauterine ascites at
30 weeks of gestation. Prenatal infection was ruled out
in fetal blood and any immunological causes were
excluded. Amniocentesis showed a normal male karyo-
typ. The male neonate, born at 36 weeks of gestation
presented with slight ascites, which resolved during the
first weeks. Neonatal jaundice was prolonged for eight
weeks and was accompanied by mild cholestatic liver en-
zyme elevation. He had a normal phenotypic appearance.
After one year, hepatosplenomegaly was found in the
routine examination of the child. The chitotriosidase
was elevated (2504 nmol/ml/h, normal range 20–
100 nmol/ml/h). Sphingomyelinase, ß-Glucosidase and
ß-Glucuronidase were normal. Subsequently, NPC was
suspected. Bone marrow punction revealed storage cells
typical for NPC. Positive Filipin staining ensured the
diagnosis. RFLP (restriction fragment length polymorph-
ism) showed mutations in the NPC1 Gene.
Review of the literature
A systematic review in PubMed of the pertinent litera-
ture, especially including those reported cases or case
series with LSD associated with NIHF and congenital as-
cites, was carried out. Studies on prenatal ultrasonog-
raphy, extensive pre- and postnatal investigations and
postmortem pathological examination were taken into
consideration. No date limit was set.
Results and discussion
Bellini et al. reviewed 225 relevant articles on non-
immune hydrops fetalis which described 6,361 indivi-
duals. All 6,361 patients were sub-classified into one of
the following 14 diagnostic categories listed in Table 1
[17].
According to that study, no definite cause can be
found in about 18% of cases of non-immunological
hydrops. Chromosomal abnormalities constituted the
chromosomal group, whereas syndromes, defined as
clusters of structural malformations, constituted the syn-
dromic group. Inborn errors of metabolism were
Table 1 Causes of non-immunological hydrops fetalis and
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Table 2 Reported incidence of lysosomal storage disorder
and inborn errors of metabolism, respectively in 13









Burin[11] 33 NIHF patients
(28 pregnancies
between 16 and 32
weeks, 5 newborns)
15%




Jauniaux[21] 600 Literature review of




Groener[22] 17 NIHF detected by
fetal ultrasound
5.9%









Favre[16] 79 Fetal ascites of NIHF
detected by routine
ultrasound during
the second or third
trimester
8.9%
Mahoney[25] 27 Sonographic evaluation
13-34 weeks of gestation
with NIHF
3.7%
Bellini[17] 6.361 Literature review of NIHF 1.1% (IEM)
Abrams[26] 414 NIHF, retrospective review
of a large national data
set (1996-2005)
1.2% (IEM)
MacFadden[27] 90 Review all autopsy cases
with HF over an
11- yr period
4.4% (IEM)
Larroche[28] 38 NIHF fetuses and newborns
with focus on fetal cerebral
ultrasounds
7.9% (IEM)
AF: Amnion fluid, IEM: Inborn errors of metabolism, HF: Hydrops fetalis, NIHF:
Non Immunological Hydrops fetalis.
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LSD. The authors distinguished between a proven or
very likely etiology and a suspected etiology. Regarding
the high number (18%) of idiopathic NIHF [17], cases of
suspected etiology were included in the idiopathic
group.
The relative frequency of the LSDs in the context of
NIHF or ascites was 1.4% in a large retrospective series
[18]. The relative incidence of metabolic storage diseases
as a cause of neonatal ascites is uncertain. A ten-year re-
view of coded diagnoses of congenital ascites at the Hos-
pital for Sick Children, Toronto gave a figure of 11%
[19]. In Table 2 the reported incidence of LSD, congeni-
tal ascites or IEM respectively in 13 different studies of
NIHF is presented.
Most of the LSDs with hydrops fetalis are autosomal,
recessively-inherited disorders with a recurrence risk of
25%. Thus, correct diagnosis is essential for genetic
counseling and family planning. There is still some un-
certainty about the relative frequency of LSD in NIHF,
which may be underestimated. An underlying metabolic
disease may be the etiology of a substantial number of
these unexplained cases. In recent years it has been
recognised that hydrops fetalis may be an extreme pres-
entation of many of the lysosomal storage disorders. It
can be hypothesized that lysosomal enzymes and their
pathways are bi-functional and hereby different in utero.
This may lead to an NIHF which requires further inves-
tigation. Usually hydrops fetalis is the most severe
phenotype of some LSDs, caused by two deleterious
mutations with a complete deficiency of the enzyme or
transport protein. In the most severe form of LSD we
usually have a good phenotype-genotype correlation, for
example, the deletion 84GG always manifests as acollodian-baby in Gaucher disease. On the other hand,
Niemann-Pick A does not manifest as an HF even with
two knock- out mutations. The two cases reported with
NPA and NIHF are an exception and may be due to sec-
ondary epigenetic factors [11].
At present, 14 different LSDs are described as being
associated with NIHF or congenital ascites [29]. These
LSDs associated with NIHF include cases with type 2
Gaucher disease, Sialidosis, Galactosialidosis, ISSD, MPS
types IV and VII, GM1 gangliosidosis, I-cell disease,
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Cited associations of NIHF with Hurler disease [30] and
Multiple sulfatase deficiency [11] seem to be doubtful
and there are no cases with a clear description. Thus at
present, 12 different LSD may be associated with NIHF
(Table 3).
LSD in association with hydrops fetalis
There are a variety of descriptions of Type 2 Gaucher
disease presenting with hydrops fetalis. In the majority
of cases with this severe phenotype including a collodian
membrane, glucocerebrosidase activity is absent or se-
verely deficient [23,24,29,55,58,71-74]. Type 2 Gaucher
disease is the rarest and most severe type, and untreated
patients uniformly die before one year of age [12].
Cases of neonatal Sialidosis presenting as hydrops feta-
lis or with neonatal ascites have been reported
[11,24,29,45,47-49,74-76]. NIHF has been reported in
galactosialidosis [48,49,75]. Claeys et al. described a pa-
tient who presented prenatally with massive ascites andTable 3 Lysosomal storage diseases and non- lysosomal inbo
Lysosomal storage diseases
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Others: Wolman disease [66] Mu
(I-cewas diagnosed only after birth as having galactosialidosis
[77]. Burin et al. reported hydrops with I-cell disease
and NPA [11].
MPS IVA (Morquio disease) is a rare disease, prenatal
manifestations of the disease include hydrops fetalis
[33,34]. MPS VII has also been recognized as a cause of
NIHF, which is actually the most common presentation
of the disease [35,73]. However, there is great variability
in the associated clinical and biochemical manifestations
[36]. The reported case I of this publication seems to
emphasize this variability. A preterm infant of 29 weeks
of gestation with Farber disease and severe hydrops feta-
lis is reported [9,60].
Congenital ascites in association with LSD
There have been at least five descriptions of cases
with NIHF or congenital ascites, either transient or per-
sistent, as the presenting symptom of GM1 gangliosido-
sis [15,51,74]. As in case IV of this publication,
Maconochie et al. described a patient with severern errors of metabolism associated with NIHF
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S IVA (Morquio) [33,34] Congenital disorder of glycosylation:
S VII (Sly): [35-41,14] CDG Ia [42,43]
Peroxismal disorder:
Zellweger syndrome [44]
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Congenital erythropoietic porphyria [70]
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[53], and Meizner et al. reported a case of NIHF in
which NPC was diagnosed by electron microscopy [58].
Although Wolman disease is usually accompanied by
mild ascites, Uno et al. [78] and Ben-Haroush et al. [66]
each described a case with isolated massive milky ascetic
fluid. ISSD have been described in patients with massive
fetal ascites [62]. Daneman et al. looked at four new-
borns with LSD, in whom the dominant presenting clin-
ical feature was ascites. The diseases included Gaucher
disease, GM I gangliosidosis, Sialidosis, and ISSD. Ab-
dominal distention due to ascites and hepatosplenome-
galy and hypoplastic lungs were seen in all patients [79].
Transient NIHF in association with LSD
In the literature two cases of transient NIHF in associ-
ation with LSD are described. The first case occurred as
early as 28 weeks of gestation and otherwise uneventful
pregnancy of a non-consanguineous couple. At birth he
had mild dysmorphic features and mild hepatospleno-
megaly. After three days, neurological deterioration was
observed and successively the diagnosis of GM1 ganglio-
sidosis was made [14]. The second case of transient
hydrops reported (week 28 of gestation) was also a GM1
gangliosidosis and diagnosed on the basis of pathological
placental findings after birth [15]. The patients reported
in this publication with transient hydrops in association
with MPS IVA, MPS VII and NPC are the first described
cases in the literature.
Suggested diagnostic approach
Staretz-Chacham and colleagues proposed an algorithm
for the clinical evaluation of a fetus or newborn with
NIHF [12]. Where there is facial dysmorphism, irregular-
ity of the epiphyses, and coarse trabeculations of the
long bones in the presence of congenital ascites, the
index of suspected storage disease is even greater [12].
We herewith suggest a diagnostic approach to the
fetus with NIHF with regard to suspected LSD (Table 4).
It may be considered that before week 18 of gestation,
urine production of the fetus is limited, bringing the risk
that a lysosomal diagnosis would be missed at the me-
tabolite level (amnion fluid). The combination of mea-
surements at the metabolite and the enzyme levels will
allow a diagnostic laboratory to pick up the most fre-
quent LSD known to be associated with NIHF [24].
It is very important to examine the placenta carefully
in cases where hydrops or ascites are present at birth or
detected by ultrasound, especially in the transient form.
Placental histology can serve as an early diagnostic clue
for a number of storage diseases, including GM1 gang-
liosidosis, MPS VII, ISSD, Gaucher disease, galactosiali-
dosis and Fabry disease. The presence of highly
vacuolated cells or cells demonstrating storage should befollowed up with enzymatic testing in patients [12]. Even
if a family does not agree to autopsy, placental examin-
ation may be done. In some instances, examination of
the placenta of a grossly macerated fetus may be more
informative than that of the fetus. Unfortunately this
was not done in the patients reported in this
publication.Family history
Because most LSDs are inherited in an autosomal reces-
sive manner we have to consider the importance of pos-
sible consanguinity. Often, reported patients had an
antecedent sibling who was also affected but not diag-
nosed. This was true in the family history of case III of
this publication. For this reason, in cases of familial
NIHF, one should consider the LSDs or other IEM.
Nelson et al. described a case of MPS VII in consan-
guineous parents who had three previous unsuccessful
pregnancies because of recurrent stillbirths [37]. Landau
et al. described a family in which fetal hydrops occurred
in four pregnancies, and the diagnosis of galactosialido-
sis was only made after the birth of the fourth affected
child [48]. Gillan reported eight cases of neonatal ascites
associated with different types of LSD: sialidosis, ISSD,
GM1 gangliosidosis, and Gaucher disease. In each case
there was a history of sibling perinatal death resulting
from the disease [19]. Manning et al. described the case
of a twelfth pregnancy of a woman who had four first-
trimester miscarriages and a previous child who died at
four weeks of age. Ultimately, the diagnosis of NPC was
made [54]. In the four patients reported by Daneman,
there was a history of perinatal death due to the same
disease in a sibling. The diagnosis of LSD was missed at
autopsy in each of these siblings, underlining the lack of
awareness of LSD as a cause for neonatal ascites [79].Conclusion
From the cases reported in the literature it can be con-
cluded that the diagnosis of a high proportion of NIHF,
and especially of LSD are missed. As already suggested
by Kooper and colleagues [24], this paper emphasizes
the fact that the incidence of LSD may be significantly
higher in NIHF than the estimated 1% reported in previ-
ous studies. However, the higher incidence could be due
to an ascertainment bias, again due to referral to a spe-
cialized center for metabolic diseases. But, as also stated
by some authors, the given low incidences, in contrast,
could be the result of incomplete investigation of NIHF
[19,24].
Transient forms of NIHF and/or ascites in association
with LSD as described in this publication in MPS IVA,
MPS VII and NPC for the first time must be considered
in the differential diagnostic of LSD.
Table 4 Diagnostic approach for NIHF and suspected lysosomal storage disease
Examination of the fetus with NIHF/
ascites in utero
Examination of the dead fetus
with NIHF
Examination of the live neonate
with NIHF
Screening
1. Amniotic fluid GAG-electrophoresis*,
lysosomal enzymes elevated in ML II
1.Postnatal autopsy should be
discussed in every individual fetus
1. Placental tissue for histological analysis. Culture
of this tissue is also possible (cell lines often show
early senescence)
-Babygram If possible elctronmicroscopy for abnormal
lysosomal shingolipid storage- NPC)
-Photo-documentation
2. Amnion cells/Chorionic villi: enzyme
measurements of ß-Glucocerebrosidase
(Gaucher disease), N-Acetyl-Glukosamin-6-Sulfatsulfatase
(MPS IVA), ß-Glucoronidase (MPS VII), Neuraminidase and
ß-Galactosidase (Galactosialidosis, GM1
Gangliosidosis and Sialidosis). Ceramidase (Farber
disease), Acid lipase (Wolman disease),
Sphingomyelinase (NPA)
2. Urine for oligosaccharides and
GAG-electrophoresis
2. Skin biopsy: DNA isolation for
genetics and cultivated cells for
biochemical tests (enzyme analysis)
3. Screening test in Plasma/Serum: I-cell screen**,
chitotriosidase
4. Blood smear: vacuolated granulocytes and Adler
granulation (GM1-gangliosidosis, Galactosialidosis,
Sialidosis, ISSD, MPS VII)
If possible electronmicroscopy
3. Tissue sample (unfixed) e.g. liver,
spleen, heart, and muscle for
histopathological and histochemical
examinations.
5: Considering bone marrow aspiration to look
for foam cells, Gaucher cells and other storage
histiocytes)
4. Placental tissue for histological
analysis. Culture of this tissue is also
possible (cell lines often show early
senescence)
6. Skeletal-radiography: dysostosis multiplex,
pathological fractures (ML II)




5. Fetal urine (if available) for
Glycosaminoglycans or
Oligosaccharides
3. Genetic analysis: amnion cells or chorion
villi cells
7. Skin biopsy: (best with eccrine glands) DNA
isolation for genetics and cultivated cells for
biochemical tests (enzyme analysis), Filipin test***
for NPC, abnormal lysosomal free sialic acid
storage (ISSD)
If possible electronmicroscopy
8. Leucocytes and plasma (also possible
in fibroblasts): measuring lysosomal enzymes
of ß-Glucocerebrosidase (Gaucher), N-Acetyl-
Glukosamin-6-Sulfatsulfatase (MPS IVA),
ß-Glucoronidase (MPS VII), Neuraminidase and
ß-Galactosidase (Galactosialidosis, GM1
Gangliosidosis and Sialidosis) Ceramidase
(Farber disease). Acid lipase (Wolman disease),
Sphingomyelinase (NPA).
9. EDTA-blood for DNA isolation
* GAG-electrophoresis: electrophoresis of glycosaminoglycans, ** I-cell screen: lysosomal enzyme activity in serum more than 10 times the reference range.
Diagnosis in fibroblasts or amnion cells: same lysosomal enzymes deficient. ***Filipin test: reaction of impaired cholesterol esterification in cultured cells with
fluorescent filipin in NPC.
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of NIHF, congenital ascites and transient hydrops as pro-
posed by the diagnostic approach in this publication
seems to be obligatory. Enzymatic studies in chorionic
villous sample or amniotic cultured cells, once the most
common conditions associated with fetal ascitis or
hydrops have been ruled out, are important.
A prospective registration and complete examination
of all cases of NIHF appears to be mandatory.
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